Tuberculosis Therapy
Investigators at University of Liverpool zero in on tuberculosis therapy
Published in TB and Outbreaks Week, June 5th, 2007
New investigation results, "Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein," are detailed in a study published in Tuberculosis. "If tuberculosis therapy is to be shortened it is imperative that the sterilising activity of current and future anti-tuberculosis drugs is enhanced. Intracellular Mycobacterium tuberculosis (MTB) phagocytosed by macrophages may be a key subpopulation of bacteria that are less readily eliminated by therapy," scientists in Liverpool, the United Kingdom report.
"Here we investigate whether macrophages provide MTB with a pharmacological sanctuary site, making them...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Bird Flu
Wistar Institute Launches New Vaccine Center - Epidemic
Cigarette Use May Explain Asthma Epidemic in Children - Tuberculosis
Epidemiology of TB: Updates from CDC studies to be presented at ATS 2007 - Pandemic
HHS Convenes America's Leaders to Help Americans Prepare for Pandemic Flu - Smallpox Vaccines
FDA Advisory Committee Unanimously Votes in Favor of Acambis' Smallpox Vaccine - Tuberculosis
BioLineRx In-Licenses Novel Peptide for the Treatment of Inflammatory Diseases - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
